Description

Remo V 100/50 mg strip of 10 Tablet 

Remo V 100/50 mg Tablet is a combination oral hypoglycemic agent used for the management of type 2 diabetes mellitus. It contains Remogliflozin Etabonate 100 mg and Vildagliptin 50 mg per tablet. The combination provides dual action to help control blood sugar levels effectively in patients whose blood glucose is not adequately managed with diet, exercise, or monotherapy.

The tablet is formulated as a film-coated tablet, designed for easy oral administration and optimal bioavailability.

---

. Composition

Excipients include substances used for binding, coating, disintegration, and stability to ensure proper delivery of the active drugs.

---

. Mechanism of Action

A. Remogliflozin Etabonate (SGLT2 Inhibitor)

• Blocks sodium-glucose co-transporter 2 in the kidneys.

• Reduces glucose reabsorption in the renal tubules.

• Promotes glucose excretion in urine.

• Helps lower fasting and postprandial blood glucose levels.

B. Vildagliptin (DPP-4 Inhibitor)

• Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4).

• Increases incretin hormone levels (GLP-1 and GIP).

• Enhances glucose-dependent insulin secretion.

• Suppresses glucagon release after meals, reducing postprandial hyperglycemia.

The combination therapy provides complementary mechanisms — increased glucose excretion and enhanced insulin activity — for better glycemic control.

---

. Pharmacokinetics

• Absorption: Both drugs are well absorbed orally.

• Distribution: Extensively bound to plasma proteins (mainly Remogliflozin).

• Metabolism: Primarily hepatic metabolism for Vildagliptin; Remogliflozin is converted to active metabolites.

• Excretion: Mainly via urine (Remogliflozin and its metabolites) and feces.

• Half-life: Suitable for once or twice daily dosing, depending on physician prescription.

---

. Indications / Therapeutic Uses

• Type 2 diabetes mellitus patients not adequately controlled with diet and exercise.

• Can be used as monotherapy in certain patients or add-on therapy with other oral antihyperglycemics.

• Improves fasting plasma glucose, postprandial glucose, and HbA1c levels.

---

. Dosage and Administration

• Take one tablet orally, preferably once daily, or as prescribed by the physician.

• Can be taken with or without food.

• Swallow tablet whole with water; do not chew or crush.

Note: Dose adjustments may be required for renal or hepatic impairment; consult a healthcare professional.

---

7. Benefits of Combination Therapy

• Dual mechanism: Works on kidneys and pancreas simultaneously.

• Effective glycemic control: Reduces both fasting and post-meal glucose spikes.

• Convenient dosing: Combines two medications into a single tablet.

• Complementary effects: Reduces risk of side effects associated with higher doses of monotherapy.

---

. Side Effects

Some commonly observed side effects may include:

• Urinary tract infections (due to increased glucose in urine)

• Nasopharyngitis, headache

• Mild gastrointestinal disturbances

• Rare: hypoglycemia when combined with insulin or sulfonylureas

Most side effects are mild and transient.

---

. Precautions

• Use caution in patients with renal impairment, hepatic impairment, or history of urinary tract infections.

• Monitor blood glucose regularly.

• Not recommended in type 1 diabetes or for diabetic ketoacidosis.

• Maintain hydration to reduce risk of dehydration.

• Pregnancy and lactation: Use only if prescribed by a physician.

---

. Storage Conditions

• Store in a cool, dry place, below 30°C.

• Protect from light and moisture.

• Keep out of reach of children.

---

. Alternate Brand Options (Remogliflozin + Vildagliptin Combination)

Prices are approximate and vary by pharmacy and region.